Replies to post #548471 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

No, I am sure everyone knew what they were reviewing. Accusing JAMA and the reviewers of incompetence is a ridiculous notion.

It’s not relevant, and I don’t believe that every time Car-T trials are written up they mention their FULL halts, rather than partial halts. They do mention maybe if patients died. Which was the cause for Car-T trials being halted.

The reason seems obvious. Why randomize patients to placebo who are newly diagnosed and would get the best result and longer life from immediate receipt of DCVax-L if that would harm their prognosis and there would ultimately be an inadequate placebo arm because of crossover. It is unethical to do that when the reason for doing it, isn’t the outcome… a usable placebo arm. Obviously you don’t randomize anymore patients to placebo.

[SkyLimit2022]

I cannot make sense of your statement. It is 100% disinformation. Anyone can verify that this is untrue.

Peer review does not work the way you suggest and nothing was hidden or withheld—it’s all there of course—go to the JAMA website or ask the editorial staff. PFS, pseudo, endpoints, OS, crossover, original protocol, were all included in the peer review. Furthermore, Liau and Ashkan are on video discussing all these aspects of the study over the years. Look at the documents attached to the manuscript at the JAMA site. It is all documented on the JAMA network website.

If you want to learn about the original trial protocol all those years ago, consult JAMA and the peer review documents that JAMA has published and made available worldwide. The links are included on the DCVax-L P3 peer review page at the JAMA Oncology website linked below.

Verify the documentation here:

https://cdn.jamanetwork.com/ama/content_public/journal/oncology/0/coi220066supp1_prod_1668698380.81699.pdf?Expires=1673747242&Signature=YmWPqPQCKvIB7n9qa-xMmmbMuh1OHdpu-daeSIBdM1sIffk78vDecEbRLg6UMLjQySSjBRMj~9Vx1p~Ej1nZkkQgBWHAf7gUMhh62UbUZiRnB2wPtoWM-6lmiUBU6kS2IUwRwYbk0wYmHtP9txKnhi7xuNnY8m5w-maeKQOXwz~sBddSIvFxkwWnabPLZggvW9-KKAEoMihAjerpKD3UIzscEND5em5q0iYLo1f2bLN4Vbe7fx77zCTijhsp477oGyPNHKIhyAkRZsRI8BsZ8SyskxoMtJTmlQ6y95nSACd03PpABR84nWrJ1buJsOPetbh9FAMvOoioq7R-LRFLtA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

Contact JAMA: [e-mail]

[Dr Bala]

The trial is a great success. Thanks, HyGro.

[Roman516]

Funny how personal opinions and fabricated stories focus on deception against NWBO, but NWBO continues to press forward. DCVax-L works, and the great news is that even more doctors, scientist and professionals are aware of the benefits, and increase in the survival rate for both nGBM and rGBM brain cancer, IMPO. The FDA is fully aware of all the facts with respect to how DCVax-L performs, IMPO. Praying that all the MM's who performed illegal spoofing against NWBO are prosecuted to the fullest extent of the law, and that NWBO and its shareholders are compensated as well, IMPO.